GenSight's long Lumevoq march goes on

France’s GenSight Biologics (Euronext: SIGHT), a company focused on discovering and developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has not had an easy year.

The firm’s share price has dropped by nearly 55% so far in 2022 amid setbacks with its lead product candidate, lenadogene nolparvovec (GS010), which is in Phase III trials in Leber hereditary optic neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults.

"With even more confidence about the benefit we can deliver to patients, the GenSight team is working with full intensity to bring our therapy to patients"GenSight plans to sell the drug under the brand name Lumevoq but its attempts to bring it to market have stalled this year.